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Introduction: Pulmonary hypertension is a progressive disease of diverse origin with devastating consequences
in adults as well as in children. The phosphodiesterase 5 inhibitor sildenafil successfully lowers pulmonary vascular
resistance. However, because of its poor enteral absorption, resulting in ineffective plasma concentrations,
responses in infants and children are often erratic.
Case presentations: We report the cases of two Caucasian boys, one born at term (case 1) and one aged 2.5 years
(case 2), who had structural cardiac and pulmonary defects accompanied by symptomatic pulmonary hypertension.
They received sildenafil enterally and sublingually and also intravenously in one of them. Plasma samples were taken
at various time points to determine the plasma concentrations of sildenafil and its partially active metabolite. Sildenafil
and N-desmethyl sildenafil were quantified using a validated liquid chromatography/mass spectrometry method.
Oxygen partial pressure was determined from routine arterial blood gas samples.
Conclusion: In agreement with previous observations in adults, we found that sublingual sildenafil was more
extensively absorbed in our two pediatric patients. After sublingual administration, sildenafil plasma concentrations
increased by 314% to 361% compared to enteral dosing. Concurrently, the metabolic ratio increased, suggesting not
only that the overall absorption was enhanced but also that first-pass metabolism was partially bypassed. In case 2,
the free fraction of sildenafil was 0.9%, which is considerably less than in adults (4%), suggesting that, in case 2, higher
plasma concentration would have been needed to achieve effects similar to those in adults. Sublingual sildenafil
appears to be a promising alternative route of administration in children with poor enteral absorption.
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The phosphodiesterase 5 (PDE5) inhibitor sildenafil lowers
pulmonary vascular resistance in patients with pulmonary
hypertension (PH) [1]. Whereas enteral bioavailability in
adults is about 40% [2], absorption in neonates and infants
is often poor [3,4], thus limiting sildenafil’s effectiveness [5].
In pediatric cases, intravenous administration effectively
increases exposure [6] and vasodilator responses [5].
However, intravenous administration is not practicable
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unless otherwise stated.In our present report, we describe the cases of two
infants with poor enteral absorption of sildenafil. We
observed that sublingual administration of sildenafil
solution markedly increased exposure.
After obtaining written informed consent from the
infants’ parents for compassionate use of sildenafil, we
collected venous blood samples to evaluate sildenafil
exposure (molar metabolic ratios (MRs) of sildenafil/
N-desmethyl sildenafil, estimated area under the plasma
concentration–time curve (AUC) and thus relative
sublingual bioavailability (F)). Sildenafil steady-state
concentrations (Cavg,ss) were calculated by dividing
AUC by the respective sampling period. Sildenafil, its
partially active metabolite N-desmethyl-sildenafil and the
free fraction (case 2) were quantified in plasma by using
a validated liquid chromatography/mass spectrometryd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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a safety marker, we evaluated partial arterial oxygen
pressure (pO2). Statistical and pharmacokinetic analyses
were carried out using Prism statistical software version
6.0 (GraphPad Software, San Diego, CA, USA).
Case presentation 1
A Caucasian boy born at term (birth weight = 3610g)
became cyanotic 1 hour after birth. Despite continuous
positive airway pressure (CPAP) support, his oxygen
saturation continued to decrease, requiring the use of
mechanical ventilation. Echocardiography revealed a
persistent foramen ovale and an open ductus arteriosus
Botalli with systolic right-to-left shunting. An open lung
biopsy confirmed the suspected diagnosis of alveolar
capillary dysplasia.
Because of the infant’s worsening pO2 level, sildenafil
treatment was started 6 weeks after birth with an enteral
dose of 2mg four times daily via a nasogastric tube
(using an in-house preparation according to a method
described previously [8]), which was increased to 4mg
four times daily 2 days later. Four weeks later, weaning
from mechanical ventilation was initiated, supported by
intermittent CPAP and nasal oxygen (FiO2 = 35% to
60%, flow rate = 3l/min to 41/min). The patient’s pO2
level was highly variable, ranging between 46mmHg and
102mmHg (mean ± SD = 70.9mmHg ± 17.5mmHg),
suggesting that the sildenafil exposure was either variable
or ineffective. Concurrently, the boy was also maintained
on ambrisentan, midazolam, chloral hydrate, clonidine,
teicoplanin, ceftazidime, levetiracetam, nystatin, ethacrynic
acid, furosemide, spironolactone, metolazone, acetamino-
phen, levomethadone, colecalciferol, sodium fluoride,
levothyroxine, acetylcysteine, salbutamol and omeprazole.
He also received phenobarbital, a strong cytochrome
P450 enzyme inducer that could possibly lower sildenafil
exposure.
Plasma samples taken during three different dosing
intervals of 2.75, 3.6 and 5 hours after dosing showed
very low concentrations (Figure 1). Assuming that plasma
concentrations were obtained during steady state, we
combined these samples to estimate the AUC as a marker
of drug exposure (Table 1).
We then switched sildenafil to sublingual doses admi-
nistered with a small syringe (4mg/2ml four times daily).
Sildenafil plasma concentrations in blood samples taken
after 4 weeks on this regimen were substantially higher
(Figure 1) than those after enteral administration. Cavg,ss
increased by 361% and Cavg,ss of N-desmethyl sildenafil
increased as well, albeit by only 35%, resulting in an
approximately threefold higher MR (Table 1). During
sublingual sildenafil, mean pO2 was 85.9mmHg (±27.2).
By then, the patient was weaned from CPAP and received
nasal oxygen (FiO2 = 100%, flow = 0.5l/min to 11/min).Nine days after being switched to sublingual sildenafil
treatment, the boy was discharged from the hospital in an
improved and stable respiratory condition, with sildenafil
continued at home. No adverse drug reaction occurred
during sildenafil administration.Case presentation 2
Case 2 is that of a 2.5-year-old boy (body weight 11kg)
who had been treated with a hybrid approach (stenting
of the ductus arteriosus and bilateral pulmonary artery
banding) at the age of 6 weeks. Upon presentation to
our hospital, he was diagnosed with atrial and ventricular
septum defects, hypoplasia of the left ventricle, aortic
isthmus stenosis, mitral valve insufficiency and persistent
left superior vena cava. He underwent a Glenn proce-
dure combined with Damus-Kaye-Stansel anastomosis
to enlarge the systemic outflow tract, which resulted in
a functional univentricular heart. Owing to low pO2, an
additional 3.5mm modified Blalock-Taussig shunt was
built. After he was weaned from cardiopulmonary bypass,
he developed severe hypoxia, was unresponsive to hyper-
ventilation and inhaled nitric oxide. Therefore, continuous
intravenous sildenafil was started (0.088mg/kg/h, appro-
ximately 23mg/d) and delivery was switched to sublingual
administration (8mg/4ml four times daily), which was
increased to 10mg/5ml four times daily after 4 days. His
clinical condition improved, and, 3 weeks later, sublingual
administration was switched to enteral administration
(10mg four times daily) via a nasogastric tube to facilitate
administration of the large volume of the suspension.
Concurrently, the child was also maintained on milrinone,
dobutamine, metildigoxin, epinephrine, clonidine, neo-
stigmine, furosemide, lisinopril, acetaminophen, levo-
methadone, simethicone, omeprazole, caspofungin and
ceftazidime. He also received erythromycin and fluco-
nazole, two strong cytochrome P450 enzyme inhibitors
that can increase sildenafil concentrations, and metamizole,
an enzyme-inducing drug that can potentially lower
sildenafil exposure.
Three blood samples were taken during intravenous
infusion and after sublingual and enteral administration
(Figure 1). Routinely drawn arterial blood gas samples
were collected, and the oxygenation values obtained on
3 consecutive days were averaged as a composite marker
for safety.
The highest sildenafil plasma concentrations were
achieved during intravenous administration (Figure 1
and Table 1). After sublingual administration, Cavg,ss in-
creased by 314% compared to enteral administration.
Concurrently, the AUC of N-desmethyl sildenafil decreased
by 50%, leading to an eightfold increase of the MR (Table 1).
Compared to the bioavailability after intravenous adminis-
tration, enterally delivered sildenafil bioavailability was 2.8%
Figure 1 Graphs depicting plasma concentrations of sildenafil and N-desmethyl sildenafil. Sildenafil (open diamonds) and its major, partially
active metabolite N-desmethyl sildenafil (circles) after enteral (open symbols) and sublingual administration (closed symbols) to two infants. The dotted
lines are extrapolated assuming that plasma concentrations during steady state are identical at different dosing intervals.
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(Table 1). The unbound fraction of sildenafil was 0.9%.
After extubation on the ninth postoperative day, oxygen
was supplied via a high-flow nasal cannula (flow = 8l/min
to 12l/min, which could be reduced over time to
41/min), which led to stable pO2 during sublingual
(38.8 ± 4.05mmHg) and enteral (38.7 ± 8.61mmHg)Table 1 Pharmacokinetic parameters of sildenafil and N-desm
Case Sildenafil AUC0–6h ((ng/ml)×h) N-desmethyl sildenafil AUC0
IV Ent SL IV Ent
1 – 5.76 26.6 – 31.8
2 919 25.5 106 70.4 74.7
aAUC0–6h, Estimated area under the concentration–time curve in a 6-hour dosing inter
sildenafil/N-desmethyl sildenafil ratio.sildenafil administration. Sildenafil was well-tolerated, and
the patient was discharged from the hospital 28 days later,
with enteral sildenafil continued at 10mg four times daily.
Discussion
In pediatric patients, congenital heart diseases, when
combined with pulmonary vascular diseases, are frequentlyethyl sildenafila
–6h ((ng/ml)×h) MR Absolute bioavailability (%)
SL IV Ent SL IV Ent SL
42.8 – 0.18 0.6 – – –
37.2 12.7 0.33 2.78 100 2.78 11.6
val, normalized to dose; IV, Intravenous; Enteral; SL, Sublingual; MR, Metabolic
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the lungs through shunts and causing severe PH [1,6]. In
these children, intravenous sildenafil reduces pulmonary
arterial pressure and shortens the time to extubation
and the length of postoperative intensive care [6]. Barst
and co-workers have recently shown dose-dependent
hemodynamic effects of oral sildenafil in children with
PH (n = 235, ages 1 to 17 years). Because there was no
change in mortality over a 16-week time period in their
open-label extension study, their results revealed that
children receiving the highest doses of sildenafil over 3
to 7 years had a higher mortality rate than those receiving
medium or low doses of sildenafil (14% and 9% versus
20%, respectively) [9]. As a consequence, the US Food
and Drug Administration (FDA) issued a warning label
against the use of sildenafil in children [10]. As subse-
quently pointed out by Abman and co-workers, however,
withholding lower doses from children may not be appro-
priate. Because the observed risks that led to the FDA’s
issuing a warning label occurred only after several years of
treatment, we did not consider the FDA warning label
relevant for short-term use in patients such as ours
[11]. When administered enterally, however, absorption is
erratic. In almost half of these patients, sildenafil exposure
is low and likely ineffective [3-5].
In adults with erectile dysfunction, sublingual sildenafil
was at least equally effective as enteral sildenafil, and
the onset of action after sublingual administration was
more than 30 minutes faster than after enteral delivery
[12]. In patients with end-stage heart failure, sublingual
sildenafil decreases pulmonary pressure by approximately
20% [13]. Altogether, these results confirm rapid mucosal
absorption. Sublingual pharmacokinetics have been
assessed only in healthy volunteers, in whom bioavailabi-
lity was found to be increased by roughly 50% compared
to enteral administration [14].
In both children described in our present report, sub-
lingual administration substantially increased sildenafil
exposure. In case 2, absolute bioavailability could be
estimated, and, though still low after sublingual admi-
nistration (about 12%), it was four times greater than
after enteral administration. Compared to adults (bio-
availability = 36% to 47%) [2], enteral bioavailability in
our pediatric patients was considerably lower, indicating
that additional causes of impaired absorption may have
been present. In adults, sildenafil absorption depends only
minimally on gut content and food [2]; therefore, enteral
feeding of our patients was not likely a cause of the limited
enteral bioavailability observed.
After sublingual administration, the MR increased,
suggesting not only that net absorption was enhanced
but also that first-pass metabolism was partially bypassed.
In healthy adults, the MR has been reported to be between
1.8 and 2.6 after enteral administration [2,15,16]. In thecases of comparable children described in previous publica-
tions, the MRs were 1.1 and 1.6 after enteral administration
[3,4] (that is, substantially larger than in our cases). These
findings suggest extensive enteral or hepatic first-pass
metabolism, which is unexpected in infants, who generally
do not yet have fully developed oxidative metabolic cap-
acity of the relevant cytochrome P450 isozyme CYP3A4
[17]. However, both children in our present report were
maintained on enzyme-inducing agents (phenobarbital
or metamizole [18]), probably partly explaining the diffe-
rences in MR observed between sublingual and enteral
administration. Because N-desmethyl sildenafil is a 2.5-
fold weaker PDE5 inhibitor than the parent compound
[19], the net vasodilating effect is expected to increase
with sublingual administration.
Sildenafil pharmacokinetics in severely ill neonates and
infants are variable, and optimal target plasma concentra-
tions are unknown. Indirect evidence suggests that total
plasma concentrations greater than 100ng/ml in adults
are needed for effectiveness [20]. Sildenafil is highly bound
to albumin and α1-acid glycoprotein (96%) in adults (4%
free fraction), and binding depends on age. In young
males, the unbound fraction was reported to be 26%
higher than in elderly individuals [16]. In our second case,
the free fraction was high enough to be quantified and
was surprisingly low (0.9%). If the concentration–response
curve is similar across all age ranges, then it appears
possible that, to achieve optimal effects, infants will
require higher total plasma concentrations than adults.
Besides the fact that information in case reports is li-
mited in general, another limitation is worth mentioning.
We collected few blood samples, and the estimated enteral
AUC value in the first case was composed of samples
collected in three consecutive dosing intervals. Although
this strategy confirmed that the exposure with sildenafil
was consistently low, it assumed that pharmacokinetic
variability between doses is small, which is unknown in
this population. Finally, our findings suggest that sublin-
gual sildenafil may become a promising route of adminis-
tration in pediatric patients. However, its use cannot be
broadly recommended before thorough pharmacokinetic
data are available. In addition, a formulation with a higher
sildenafil concentration probably also should be deve-
loped, because the sublingual volumes may become large
if high sildenafil doses are to be administered.Conclusion
Switching from enteral to sublingual administration in
two infants with poor enteral absorption of the drug
substantially increased sildenafil exposure and favorably
shifted the MR toward higher concentrations of the
more active parent compound. These findings suggest
that the sublingual route of administration may be a
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many pediatric patients with poor enteral availability.
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